Comparison Between Podofilox Topical Gel 0.5% and Allergan's Condylox® Gel 0.5% for External Anogenital Warts
Status:
Completed
Trial end date:
2020-01-31
Target enrollment:
Participant gender:
Summary
A clinical endpoint bioequivalence (BE) study for a Podofilox Gel 0.5% formulation for the
treatment of external anogenital warts in comparison to Condylox® Gel 0.5% that follows the
study design and recommendations according to Office of Generic Drugs (OGD) of U.S. Food and
Drug Administration (FDA) Draft Guidance for Podofilox recommendations